Zhongchao Inc.

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, BTSGU has a market cap of 35.4B. Regarding current trading prices, ZCMD is priced at $1.47, while BTSGU trades at $186.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas BTSGU's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to BTSGU's ROE of +0.17%. Regarding short-term risk, ZCMD is more volatile compared to BTSGU. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check BTSGU's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, GEHC has a market cap of 28.1B. Regarding current trading prices, ZCMD is priced at $1.47, while GEHC trades at $62.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas GEHC's P/E ratio is 14.80. In terms of profitability, ZCMD's ROE is -0.32%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, ZCMD is more volatile compared to GEHC. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check GEHC's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, VEEV has a market cap of 26B. Regarding current trading prices, ZCMD is priced at $1.47, while VEEV trades at $160.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas VEEV's P/E ratio is 29.29. In terms of profitability, ZCMD's ROE is -0.32%, compared to VEEV's ROE of +0.13%. Regarding short-term risk, ZCMD is more volatile compared to VEEV. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check VEEV's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, GEHCV has a market cap of 25.5B. Regarding current trading prices, ZCMD is priced at $1.47, while GEHCV trades at $56.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas GEHCV's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to GEHCV's ROE of +0.19%. Regarding short-term risk, ZCMD is less volatile compared to GEHCV. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check GEHCV's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, BTSG has a market cap of 10.7B. Regarding current trading prices, ZCMD is priced at $1.47, while BTSG trades at $56.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas BTSG's P/E ratio is 71.52. In terms of profitability, ZCMD's ROE is -0.32%, compared to BTSG's ROE of +0.17%. Regarding short-term risk, ZCMD is more volatile compared to BTSG. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check BTSG's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, SGFY has a market cap of 8.9B. Regarding current trading prices, ZCMD is priced at $1.47, while SGFY trades at $30.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas SGFY's P/E ratio is 70.91. In terms of profitability, ZCMD's ROE is -0.32%, compared to SGFY's ROE of -0.15%. Regarding short-term risk, ZCMD is more volatile compared to SGFY. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SGFY's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, TEM has a market cap of 8.4B. Regarding current trading prices, ZCMD is priced at $1.47, while TEM trades at $46.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas TEM's P/E ratio is -28.17. In terms of profitability, ZCMD's ROE is -0.32%, compared to TEM's ROE of -0.70%. Regarding short-term risk, ZCMD is more volatile compared to TEM. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check TEM's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, HQY has a market cap of 6.9B. Regarding current trading prices, ZCMD is priced at $1.47, while HQY trades at $80.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas HQY's P/E ratio is 33.19. In terms of profitability, ZCMD's ROE is -0.32%, compared to HQY's ROE of +0.10%. Regarding short-term risk, ZCMD is more volatile compared to HQY. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check HQY's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, RCM has a market cap of 6B. Regarding current trading prices, ZCMD is priced at $1.47, while RCM trades at $14.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas RCM's P/E ratio is -102.21. In terms of profitability, ZCMD's ROE is -0.32%, compared to RCM's ROE of +0.00%. Regarding short-term risk, ZCMD is more volatile compared to RCM. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check RCM's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, DOCS has a market cap of 4.9B. Regarding current trading prices, ZCMD is priced at $1.47, while DOCS trades at $26.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas DOCS's P/E ratio is 22.08. In terms of profitability, ZCMD's ROE is -0.32%, compared to DOCS's ROE of +0.23%. Regarding short-term risk, ZCMD is more volatile compared to DOCS. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check DOCS's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, HNGE has a market cap of 4.2B. Regarding current trading prices, ZCMD is priced at $1.47, while HNGE trades at $54.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas HNGE's P/E ratio is -6.14. In terms of profitability, ZCMD's ROE is -0.32%, compared to HNGE's ROE of -1.39%. Regarding short-term risk, ZCMD is more volatile compared to HNGE. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check HNGE's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, ONEM has a market cap of 3.4B. Regarding current trading prices, ZCMD is priced at $1.47, while ONEM trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas ONEM's P/E ratio is -7.77. In terms of profitability, ZCMD's ROE is -0.32%, compared to ONEM's ROE of -0.24%. Regarding short-term risk, ZCMD is more volatile compared to ONEM. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check ONEM's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, PRVA has a market cap of 2.9B. Regarding current trading prices, ZCMD is priced at $1.47, while PRVA trades at $22.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas PRVA's P/E ratio is 133.88. In terms of profitability, ZCMD's ROE is -0.32%, compared to PRVA's ROE of +0.00%. Regarding short-term risk, ZCMD is more volatile compared to PRVA. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check PRVA's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, TXG has a market cap of 2.6B. Regarding current trading prices, ZCMD is priced at $1.47, while TXG trades at $20.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas TXG's P/E ratio is -120.59. In terms of profitability, ZCMD's ROE is -0.32%, compared to TXG's ROE of -0.03%. Regarding short-term risk, ZCMD is more volatile compared to TXG. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check TXG's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, HTFL has a market cap of 2.5B. Regarding current trading prices, ZCMD is priced at $1.47, while HTFL trades at $29.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas HTFL's P/E ratio is -9.27. In terms of profitability, ZCMD's ROE is -0.32%, compared to HTFL's ROE of +0.38%. Regarding short-term risk, ZCMD is more volatile compared to HTFL. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check HTFL's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, PINC has a market cap of 2.3B. Regarding current trading prices, ZCMD is priced at $1.47, while PINC trades at $28.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas PINC's P/E ratio is 166.24. In terms of profitability, ZCMD's ROE is -0.32%, compared to PINC's ROE of -0.02%. Regarding short-term risk, ZCMD is more volatile compared to PINC. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check PINC's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, OMCL has a market cap of 2B. Regarding current trading prices, ZCMD is priced at $1.47, while OMCL trades at $43.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas OMCL's P/E ratio is 98.41. In terms of profitability, ZCMD's ROE is -0.32%, compared to OMCL's ROE of +0.02%. Regarding short-term risk, ZCMD is more volatile compared to OMCL. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check OMCL's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, PGNY has a market cap of 1.8B. Regarding current trading prices, ZCMD is priced at $1.47, while PGNY trades at $22.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas PGNY's P/E ratio is 29.29. In terms of profitability, ZCMD's ROE is -0.32%, compared to PGNY's ROE of +0.13%. Regarding short-term risk, ZCMD is more volatile compared to PGNY. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check PGNY's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, NXGN has a market cap of 1.6B. Regarding current trading prices, ZCMD is priced at $1.47, while NXGN trades at $23.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas NXGN's P/E ratio is -266.00. In terms of profitability, ZCMD's ROE is -0.32%, compared to NXGN's ROE of -0.01%. Regarding short-term risk, ZCMD is more volatile compared to NXGN. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check NXGN's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, AGTI has a market cap of 1.4B. Regarding current trading prices, ZCMD is priced at $1.47, while AGTI trades at $10.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas AGTI's P/E ratio is -71.79. In terms of profitability, ZCMD's ROE is -0.32%, compared to AGTI's ROE of -0.02%. Regarding short-term risk, ZCMD is more volatile compared to AGTI. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check AGTI's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, TDOC has a market cap of 1.2B. Regarding current trading prices, ZCMD is priced at $1.47, while TDOC trades at $6.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas TDOC's P/E ratio is -0.24. In terms of profitability, ZCMD's ROE is -0.32%, compared to TDOC's ROE of -0.12%. Regarding short-term risk, ZCMD is more volatile compared to TDOC. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check TDOC's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, WGS has a market cap of 1.2B. Regarding current trading prices, ZCMD is priced at $1.47, while WGS trades at $39.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas WGS's P/E ratio is -14.89. In terms of profitability, ZCMD's ROE is -0.32%, compared to WGS's ROE of -0.28%. Regarding short-term risk, ZCMD is less volatile compared to WGS. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check WGS's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, GDRX has a market cap of 984.4M. Regarding current trading prices, ZCMD is priced at $1.47, while GDRX trades at $2.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas GDRX's P/E ratio is 47.33. In terms of profitability, ZCMD's ROE is -0.32%, compared to GDRX's ROE of +0.05%. Regarding short-term risk, ZCMD is more volatile compared to GDRX. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check GDRX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, SDGR has a market cap of 950.4M. Regarding current trading prices, ZCMD is priced at $1.47, while SDGR trades at $12.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas SDGR's P/E ratio is -9.09. In terms of profitability, ZCMD's ROE is -0.32%, compared to SDGR's ROE of -0.31%. Regarding short-term risk, ZCMD is more volatile compared to SDGR. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SDGR's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, OMDA has a market cap of 865.6M. Regarding current trading prices, ZCMD is priced at $1.47, while OMDA trades at $14.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas OMDA's P/E ratio is -69.95. In terms of profitability, ZCMD's ROE is -0.32%, compared to OMDA's ROE of -0.03%. Regarding short-term risk, ZCMD is more volatile compared to OMDA. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check OMDA's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, CCLDO has a market cap of 858.5M. Regarding current trading prices, ZCMD is priced at $1.47, while CCLDO trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas CCLDO's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to CCLDO's ROE of +0.17%. Regarding short-term risk, ZCMD is more volatile compared to CCLDO. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check CCLDO's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, NUTX has a market cap of 791.2M. Regarding current trading prices, ZCMD is priced at $1.47, while NUTX trades at $132.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas NUTX's P/E ratio is 9.71. In terms of profitability, ZCMD's ROE is -0.32%, compared to NUTX's ROE of +0.31%. Regarding short-term risk, ZCMD is more volatile compared to NUTX. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check NUTX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, CERT has a market cap of 786.6M. Regarding current trading prices, ZCMD is priced at $1.47, while CERT trades at $5.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas CERT's P/E ratio is -513.00. In terms of profitability, ZCMD's ROE is -0.32%, compared to CERT's ROE of -0.01%. Regarding short-term risk, ZCMD is less volatile compared to CERT. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check CERT's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, HSTM has a market cap of 675.5M. Regarding current trading prices, ZCMD is priced at $1.47, while HSTM trades at $23.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas HSTM's P/E ratio is 34.51. In terms of profitability, ZCMD's ROE is -0.32%, compared to HSTM's ROE of +0.06%. Regarding short-term risk, ZCMD is more volatile compared to HSTM. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check HSTM's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, MPLN-WT has a market cap of 625.2M. Regarding current trading prices, ZCMD is priced at $1.47, while MPLN-WT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas MPLN-WT's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to MPLN-WT's ROE of +2.06%. Regarding short-term risk, ZCMD is less volatile compared to MPLN-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check MPLN-WT's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, PHR has a market cap of 580.9M. Regarding current trading prices, ZCMD is priced at $1.47, while PHR trades at $9.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas PHR's P/E ratio is 239.00. In terms of profitability, ZCMD's ROE is -0.32%, compared to PHR's ROE of +0.01%. Regarding short-term risk, ZCMD is more volatile compared to PHR. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check PHR's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, ACCD has a market cap of 575.6M. Regarding current trading prices, ZCMD is priced at $1.47, while ACCD trades at $7.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas ACCD's P/E ratio is -3.08. In terms of profitability, ZCMD's ROE is -0.32%, compared to ACCD's ROE of -0.22%. Regarding short-term risk, ZCMD is more volatile compared to ACCD. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check ACCD's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, SHCR has a market cap of 531.8M. Regarding current trading prices, ZCMD is priced at $1.47, while SHCR trades at $1.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas SHCR's P/E ratio is -3.76. In terms of profitability, ZCMD's ROE is -0.32%, compared to SHCR's ROE of -0.25%. Regarding short-term risk, ZCMD is more volatile compared to SHCR. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SHCR's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, CTEV has a market cap of 505.5M. Regarding current trading prices, ZCMD is priced at $1.47, while CTEV trades at $29.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas CTEV's P/E ratio is -1.71. In terms of profitability, ZCMD's ROE is -0.32%, compared to CTEV's ROE of +2.06%. Regarding short-term risk, ZCMD is less volatile compared to CTEV. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check CTEV's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, EVH has a market cap of 446M. Regarding current trading prices, ZCMD is priced at $1.47, while EVH trades at $4.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas EVH's P/E ratio is -0.85. In terms of profitability, ZCMD's ROE is -0.32%, compared to EVH's ROE of -0.78%. Regarding short-term risk, ZCMD is less volatile compared to EVH. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check EVH's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, NRC has a market cap of 421.7M. Regarding current trading prices, ZCMD is priced at $1.47, while NRC trades at $18.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas NRC's P/E ratio is 47.97. In terms of profitability, ZCMD's ROE is -0.32%, compared to NRC's ROE of +0.57%. Regarding short-term risk, ZCMD is more volatile compared to NRC. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check NRC's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, SY has a market cap of 400M. Regarding current trading prices, ZCMD is priced at $1.47, while SY trades at $2.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas SY's P/E ratio is -8.69. In terms of profitability, ZCMD's ROE is -0.32%, compared to SY's ROE of -0.14%. Regarding short-term risk, ZCMD is more volatile compared to SY. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SY's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, SLGCW has a market cap of 396.2M. Regarding current trading prices, ZCMD is priced at $1.47, while SLGCW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas SLGCW's P/E ratio is -0.16. In terms of profitability, ZCMD's ROE is -0.32%, compared to SLGCW's ROE of -0.19%. Regarding short-term risk, ZCMD is less volatile compared to SLGCW. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check SLGCW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, SLGC has a market cap of 396.2M. Regarding current trading prices, ZCMD is priced at $1.47, while SLGC trades at $2.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas SLGC's P/E ratio is -3.04. In terms of profitability, ZCMD's ROE is -0.32%, compared to SLGC's ROE of -0.19%. Regarding short-term risk, ZCMD is less volatile compared to SLGC. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check SLGC's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, TBRG has a market cap of 388.3M. Regarding current trading prices, ZCMD is priced at $1.47, while TBRG trades at $25.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas TBRG's P/E ratio is 89.28. In terms of profitability, ZCMD's ROE is -0.32%, compared to TBRG's ROE of +0.02%. Regarding short-term risk, ZCMD is more volatile compared to TBRG. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check TBRG's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, MPLN has a market cap of 375M. Regarding current trading prices, ZCMD is priced at $1.47, while MPLN trades at $23.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas MPLN's P/E ratio is -0.23. In terms of profitability, ZCMD's ROE is -0.32%, compared to MPLN's ROE of +2.06%. Regarding short-term risk, ZCMD is less volatile compared to MPLN. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check MPLN's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, SOPH has a market cap of 343.3M. Regarding current trading prices, ZCMD is priced at $1.47, while SOPH trades at $4.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas SOPH's P/E ratio is -4.06. In terms of profitability, ZCMD's ROE is -0.32%, compared to SOPH's ROE of -1.41%. Regarding short-term risk, ZCMD is more volatile compared to SOPH. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SOPH's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, SLP has a market cap of 296.8M. Regarding current trading prices, ZCMD is priced at $1.47, while SLP trades at $14.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas SLP's P/E ratio is -4.71. In terms of profitability, ZCMD's ROE is -0.32%, compared to SLP's ROE of -0.49%. Regarding short-term risk, ZCMD is more volatile compared to SLP. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SLP's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, TRHC has a market cap of 284M. Regarding current trading prices, ZCMD is priced at $1.47, while TRHC trades at $10.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas TRHC's P/E ratio is -4.27. In terms of profitability, ZCMD's ROE is -0.32%, compared to TRHC's ROE of +121.31%. Regarding short-term risk, ZCMD is more volatile compared to TRHC. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check TRHC's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, CARL has a market cap of 262.6M. Regarding current trading prices, ZCMD is priced at $1.47, while CARL trades at $9.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas CARL's P/E ratio is -9.86. In terms of profitability, ZCMD's ROE is -0.32%, compared to CARL's ROE of -0.62%. Regarding short-term risk, ZCMD is more volatile compared to CARL. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check CARL's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, SMFR has a market cap of 246.4M. Regarding current trading prices, ZCMD is priced at $1.47, while SMFR trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas SMFR's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to SMFR's ROE of -0.28%. Regarding short-term risk, ZCMD is less volatile compared to SMFR. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check SMFR's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, SPOK has a market cap of 222.7M. Regarding current trading prices, ZCMD is priced at $1.47, while SPOK trades at $10.79.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas SPOK's P/E ratio is 18.07. In terms of profitability, ZCMD's ROE is -0.32%, compared to SPOK's ROE of +0.09%. Regarding short-term risk, ZCMD is more volatile compared to SPOK. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SPOK's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, AMWL has a market cap of 136.2M. Regarding current trading prices, ZCMD is priced at $1.47, while AMWL trades at $7.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas AMWL's P/E ratio is -1.50. In terms of profitability, ZCMD's ROE is -0.32%, compared to AMWL's ROE of -0.35%. Regarding short-term risk, ZCMD is more volatile compared to AMWL. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check AMWL's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, CPSI has a market cap of 133.7M. Regarding current trading prices, ZCMD is priced at $1.47, while CPSI trades at $9.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas CPSI's P/E ratio is -183.80. In terms of profitability, ZCMD's ROE is -0.32%, compared to CPSI's ROE of +0.02%. Regarding short-term risk, ZCMD is less volatile compared to CPSI. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check CPSI's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, OPRX has a market cap of 116.5M. Regarding current trading prices, ZCMD is priced at $1.47, while OPRX trades at $6.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas OPRX's P/E ratio is 23.00. In terms of profitability, ZCMD's ROE is -0.32%, compared to OPRX's ROE of +0.04%. Regarding short-term risk, ZCMD is more volatile compared to OPRX. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check OPRX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, AUGX has a market cap of 115.9M. Regarding current trading prices, ZCMD is priced at $1.47, while AUGX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas AUGX's P/E ratio is -4.99. In terms of profitability, ZCMD's ROE is -0.32%, compared to AUGX's ROE of -1.55%. Regarding short-term risk, ZCMD is more volatile compared to AUGX. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check AUGX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, DH has a market cap of 104.3M. Regarding current trading prices, ZCMD is priced at $1.47, while DH trades at $0.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas DH's P/E ratio is -0.59. In terms of profitability, ZCMD's ROE is -0.32%, compared to DH's ROE of -0.67%. Regarding short-term risk, ZCMD is more volatile compared to DH. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check DH's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, HCAT has a market cap of 101.5M. Regarding current trading prices, ZCMD is priced at $1.47, while HCAT trades at $1.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas HCAT's P/E ratio is -0.54. In terms of profitability, ZCMD's ROE is -0.32%, compared to HCAT's ROE of -0.55%. Regarding short-term risk, ZCMD is less volatile compared to HCAT. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check HCAT's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, CCLD has a market cap of 95.6M. Regarding current trading prices, ZCMD is priced at $1.47, while CCLD trades at $2.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas CCLD's P/E ratio is 17.31. In terms of profitability, ZCMD's ROE is -0.32%, compared to CCLD's ROE of +0.17%. Regarding short-term risk, ZCMD is more volatile compared to CCLD. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check CCLD's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, FORA has a market cap of 67.5M. Regarding current trading prices, ZCMD is priced at $1.47, while FORA trades at $2.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas FORA's P/E ratio is -24.00. In terms of profitability, ZCMD's ROE is -0.32%, compared to FORA's ROE of -0.09%. Regarding short-term risk, ZCMD is more volatile compared to FORA. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check FORA's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, CCLDP has a market cap of 59.9M. Regarding current trading prices, ZCMD is priced at $1.47, while CCLDP trades at $19.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas CCLDP's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to CCLDP's ROE of +0.17%. Regarding short-term risk, ZCMD is more volatile compared to CCLDP. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check CCLDP's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, SNCE has a market cap of 34.7M. Regarding current trading prices, ZCMD is priced at $1.47, while SNCE trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas SNCE's P/E ratio is -0.27. In terms of profitability, ZCMD's ROE is -0.32%, compared to SNCE's ROE of -0.47%. Regarding short-term risk, ZCMD is more volatile compared to SNCE. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SNCE's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, AKLI has a market cap of 34.1M. Regarding current trading prices, ZCMD is priced at $1.47, while AKLI trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas AKLI's P/E ratio is -0.71. In terms of profitability, ZCMD's ROE is -0.32%, compared to AKLI's ROE of -0.70%. Regarding short-term risk, ZCMD is more volatile compared to AKLI. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check AKLI's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, SHLT has a market cap of 33.6M. Regarding current trading prices, ZCMD is priced at $1.47, while SHLT trades at $2.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas SHLT's P/E ratio is -3.87. In terms of profitability, ZCMD's ROE is -0.32%, compared to SHLT's ROE of -0.50%. Regarding short-term risk, ZCMD is more volatile compared to SHLT. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SHLT's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, SHCRW has a market cap of 32.5M. Regarding current trading prices, ZCMD is priced at $1.47, while SHCRW trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas SHCRW's P/E ratio is -0.00. In terms of profitability, ZCMD's ROE is -0.32%, compared to SHCRW's ROE of -0.25%. Regarding short-term risk, ZCMD is more volatile compared to SHCRW. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SHCRW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, ONMD has a market cap of 32.1M. Regarding current trading prices, ZCMD is priced at $1.47, while ONMD trades at $0.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas ONMD's P/E ratio is -16.33. In terms of profitability, ZCMD's ROE is -0.32%, compared to ONMD's ROE of +0.41%. Regarding short-term risk, ZCMD is more volatile compared to ONMD. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check ONMD's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, BEAT has a market cap of 30.5M. Regarding current trading prices, ZCMD is priced at $1.47, while BEAT trades at $0.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas BEAT's P/E ratio is -1.43. In terms of profitability, ZCMD's ROE is -0.32%, compared to BEAT's ROE of -5.71%. Regarding short-term risk, ZCMD is more volatile compared to BEAT. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check BEAT's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, EUDA has a market cap of 26.9M. Regarding current trading prices, ZCMD is priced at $1.47, while EUDA trades at $14.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas EUDA's P/E ratio is -9.73. In terms of profitability, ZCMD's ROE is -0.32%, compared to EUDA's ROE of +0.13%. Regarding short-term risk, ZCMD is more volatile compared to EUDA. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check EUDA's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, STRM has a market cap of 23.2M. Regarding current trading prices, ZCMD is priced at $1.47, while STRM trades at $5.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas STRM's P/E ratio is -2.40. In terms of profitability, ZCMD's ROE is -0.32%, compared to STRM's ROE of -0.32%. Regarding short-term risk, ZCMD is more volatile compared to STRM. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check STRM's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, RNLX has a market cap of 22.5M. Regarding current trading prices, ZCMD is priced at $1.47, while RNLX trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas RNLX's P/E ratio is -0.33. In terms of profitability, ZCMD's ROE is -0.32%, compared to RNLX's ROE of -6.31%. Regarding short-term risk, ZCMD is less volatile compared to RNLX. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check RNLX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, LIFW has a market cap of 22.4M. Regarding current trading prices, ZCMD is priced at $1.47, while LIFW trades at $3.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas LIFW's P/E ratio is -0.02. In terms of profitability, ZCMD's ROE is -0.32%, compared to LIFW's ROE of +3.93%. Regarding short-term risk, ZCMD is more volatile compared to LIFW. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check LIFW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, BBLN has a market cap of 14.1M. Regarding current trading prices, ZCMD is priced at $1.47, while BBLN trades at $0.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas BBLN's P/E ratio is -0.04. In terms of profitability, ZCMD's ROE is -0.32%, compared to BBLN's ROE of +4.89%. Regarding short-term risk, ZCMD is less volatile compared to BBLN. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check BBLN's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, ETAO has a market cap of 9.8M. Regarding current trading prices, ZCMD is priced at $1.47, while ETAO trades at $1.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas ETAO's P/E ratio is -0.01. In terms of profitability, ZCMD's ROE is -0.32%, compared to ETAO's ROE of -13.69%. Regarding short-term risk, ZCMD is less volatile compared to ETAO. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check ETAO's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, HLTH has a market cap of 6.9M. Regarding current trading prices, ZCMD is priced at $1.47, while HLTH trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas HLTH's P/E ratio is -0.02. In terms of profitability, ZCMD's ROE is -0.32%, compared to HLTH's ROE of -0.90%. Regarding short-term risk, ZCMD is less volatile compared to HLTH. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check HLTH's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, BFRG has a market cap of 6.8M. Regarding current trading prices, ZCMD is priced at $1.47, while BFRG trades at $0.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas BFRG's P/E ratio is -1.02. In terms of profitability, ZCMD's ROE is -0.32%, compared to BFRG's ROE of -2.73%. Regarding short-term risk, ZCMD is more volatile compared to BFRG. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check BFRG's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, SCNX has a market cap of 6.2M. Regarding current trading prices, ZCMD is priced at $1.47, while SCNX trades at $0.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas SCNX's P/E ratio is -0.15. In terms of profitability, ZCMD's ROE is -0.32%, compared to SCNX's ROE of -2.36%. Regarding short-term risk, ZCMD is more volatile compared to SCNX. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check SCNX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, UPH-WT has a market cap of 5.3M. Regarding current trading prices, ZCMD is priced at $1.47, while UPH-WT trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas UPH-WT's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to UPH-WT's ROE of -1.05%. Regarding short-term risk, ZCMD is less volatile compared to UPH-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check UPH-WT's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, UPH has a market cap of 5.3M. Regarding current trading prices, ZCMD is priced at $1.47, while UPH trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas UPH's P/E ratio is -0.07. In terms of profitability, ZCMD's ROE is -0.32%, compared to UPH's ROE of -1.05%. Regarding short-term risk, ZCMD is less volatile compared to UPH. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check UPH's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, MGRX has a market cap of 4.3M. Regarding current trading prices, ZCMD is priced at $1.47, while MGRX trades at $0.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas MGRX's P/E ratio is -0.19. In terms of profitability, ZCMD's ROE is -0.32%, compared to MGRX's ROE of -1.17%. Regarding short-term risk, ZCMD is less volatile compared to MGRX. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check MGRX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, PEARW has a market cap of 4.1M. Regarding current trading prices, ZCMD is priced at $1.47, while PEARW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas PEARW's P/E ratio is -0.00. In terms of profitability, ZCMD's ROE is -0.32%, compared to PEARW's ROE of -0.39%. Regarding short-term risk, ZCMD is less volatile compared to PEARW. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check PEARW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, PEAR has a market cap of 4.1M. Regarding current trading prices, ZCMD is priced at $1.47, while PEAR trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas PEAR's P/E ratio is -0.08. In terms of profitability, ZCMD's ROE is -0.32%, compared to PEAR's ROE of -0.39%. Regarding short-term risk, ZCMD is less volatile compared to PEAR. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check PEAR's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, BEATW has a market cap of 2.9M. Regarding current trading prices, ZCMD is priced at $1.47, while BEATW trades at $0.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas BEATW's P/E ratio is -0.17. In terms of profitability, ZCMD's ROE is -0.32%, compared to BEATW's ROE of -5.71%. Regarding short-term risk, ZCMD is less volatile compared to BEATW. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check BEATW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, VSEE has a market cap of 2.9M. Regarding current trading prices, ZCMD is priced at $1.47, while VSEE trades at $0.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas VSEE's P/E ratio is -0.24. In terms of profitability, ZCMD's ROE is -0.32%, compared to VSEE's ROE of +6.29%. Regarding short-term risk, ZCMD is more volatile compared to VSEE. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check VSEE's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, BFRGW has a market cap of 2.7M. Regarding current trading prices, ZCMD is priced at $1.47, while BFRGW trades at $0.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas BFRGW's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to BFRGW's ROE of -2.73%. Regarding short-term risk, ZCMD is less volatile compared to BFRGW. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check BFRGW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, HCTI has a market cap of 2.4M. Regarding current trading prices, ZCMD is priced at $1.47, while HCTI trades at $2.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas HCTI's P/E ratio is -0.01. In terms of profitability, ZCMD's ROE is -0.32%, compared to HCTI's ROE of -1.01%. Regarding short-term risk, ZCMD is more volatile compared to HCTI. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check HCTI's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, OTRK has a market cap of 2.3M. Regarding current trading prices, ZCMD is priced at $1.47, while OTRK trades at $0.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas OTRK's P/E ratio is -0.02. In terms of profitability, ZCMD's ROE is -0.32%, compared to OTRK's ROE of -1.66%. Regarding short-term risk, ZCMD is more volatile compared to OTRK. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check OTRK's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, ACON has a market cap of 1.7M. Regarding current trading prices, ZCMD is priced at $1.47, while ACON trades at $3.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas ACON's P/E ratio is -0.23. In terms of profitability, ZCMD's ROE is -0.32%, compared to ACON's ROE of -0.00%. Regarding short-term risk, ZCMD is more volatile compared to ACON. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check ACON's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, CMAX has a market cap of 1.6M. Regarding current trading prices, ZCMD is priced at $1.47, while CMAX trades at $0.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas CMAX's P/E ratio is -0.00. In terms of profitability, ZCMD's ROE is -0.32%, compared to CMAX's ROE of -2.01%. Regarding short-term risk, ZCMD is more volatile compared to CMAX. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check CMAX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, EUDAW has a market cap of 1.5M. Regarding current trading prices, ZCMD is priced at $1.47, while EUDAW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas EUDAW's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to EUDAW's ROE of +0.13%. Regarding short-term risk, ZCMD is less volatile compared to EUDAW. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check EUDAW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, LIFWZ has a market cap of 1.3M. Regarding current trading prices, ZCMD is priced at $1.47, while LIFWZ trades at $0.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas LIFWZ's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to LIFWZ's ROE of +3.93%. Regarding short-term risk, ZCMD is more volatile compared to LIFWZ. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check LIFWZ's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, VSEEW has a market cap of 1M. Regarding current trading prices, ZCMD is priced at $1.47, while VSEEW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas VSEEW's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to VSEEW's ROE of +6.29%. Regarding short-term risk, ZCMD is less volatile compared to VSEEW. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check VSEEW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, MSPRZ has a market cap of 550.4K. Regarding current trading prices, ZCMD is priced at $1.47, while MSPRZ trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas MSPRZ's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to MSPRZ's ROE of +3.93%. Regarding short-term risk, ZCMD is less volatile compared to MSPRZ. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check MSPRZ's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, MSPR has a market cap of 504.1K. Regarding current trading prices, ZCMD is priced at $1.47, while MSPR trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas MSPR's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to MSPR's ROE of +3.93%. Regarding short-term risk, ZCMD is less volatile compared to MSPR. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check MSPR's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, WORX has a market cap of 303.5K. Regarding current trading prices, ZCMD is priced at $1.47, while WORX trades at $1.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas WORX's P/E ratio is -0.12. In terms of profitability, ZCMD's ROE is -0.32%, compared to WORX's ROE of -0.73%. Regarding short-term risk, ZCMD is less volatile compared to WORX. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check WORX's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, KERNW has a market cap of 162.3K. Regarding current trading prices, ZCMD is priced at $1.47, while KERNW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas KERNW's P/E ratio is -0.00. In terms of profitability, ZCMD's ROE is -0.32%, compared to KERNW's ROE of -0.17%. Regarding short-term risk, ZCMD is less volatile compared to KERNW. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check KERNW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, KERN has a market cap of 162.3K. Regarding current trading prices, ZCMD is priced at $1.47, while KERN trades at $0.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas KERN's P/E ratio is -0.01. In terms of profitability, ZCMD's ROE is -0.32%, compared to KERN's ROE of -0.17%. Regarding short-term risk, ZCMD is less volatile compared to KERN. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check KERN's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, WGSWW has a market cap of 112.9K. Regarding current trading prices, ZCMD is priced at $1.47, while WGSWW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas WGSWW's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to WGSWW's ROE of -0.28%. Regarding short-term risk, ZCMD is less volatile compared to WGSWW. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check WGSWW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, LIFWW has a market cap of 60.1K. Regarding current trading prices, ZCMD is priced at $1.47, while LIFWW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas LIFWW's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to LIFWW's ROE of +3.93%. Regarding short-term risk, ZCMD is more volatile compared to LIFWW. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check LIFWW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, OTRKP has a market cap of 50.1K. Regarding current trading prices, ZCMD is priced at $1.47, while OTRKP trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas OTRKP's P/E ratio is -0.00. In terms of profitability, ZCMD's ROE is -0.32%, compared to OTRKP's ROE of -1.66%. Regarding short-term risk, ZCMD is less volatile compared to OTRKP. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check OTRKP's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, CMAXW has a market cap of 36.4K. Regarding current trading prices, ZCMD is priced at $1.47, while CMAXW trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas CMAXW's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to CMAXW's ROE of -2.01%. Regarding short-term risk, ZCMD is more volatile compared to CMAXW. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check CMAXW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, ACONW has a market cap of 17.8K. Regarding current trading prices, ZCMD is priced at $1.47, while ACONW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas ACONW's P/E ratio is -0.01. In terms of profitability, ZCMD's ROE is -0.32%, compared to ACONW's ROE of -0.00%. Regarding short-term risk, ZCMD is less volatile compared to ACONW. This indicates potentially lower risk in terms of short-term price fluctuations for ZCMD.Check ACONW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, ICCT has a market cap of 5.4K. Regarding current trading prices, ZCMD is priced at $1.47, while ICCT trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas ICCT's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to ICCT's ROE of +11.65%. Regarding short-term risk, ZCMD is more volatile compared to ICCT. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check ICCT's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, MSPRW has a market cap of 4.1K. Regarding current trading prices, ZCMD is priced at $1.47, while MSPRW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas MSPRW's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to MSPRW's ROE of +3.93%. Regarding short-term risk, ZCMD is more volatile compared to MSPRW. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check MSPRW's competition here

ZCMD plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ZCMD stands at 4.9M. In comparison, FOXO has a market cap of 3K. Regarding current trading prices, ZCMD is priced at $1.47, while FOXO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ZCMD currently has a P/E ratio of -0.82, whereas FOXO's P/E ratio is N/A. In terms of profitability, ZCMD's ROE is -0.32%, compared to FOXO's ROE of -0.91%. Regarding short-term risk, ZCMD is more volatile compared to FOXO. This indicates potentially higher risk in terms of short-term price fluctuations for ZCMD.Check FOXO's competition here